# Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

> **NCT02479698** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- BK Virus Infection
- Human Immunodeficiency Virus
- JC Virus Infection
- Malignant Neoplasm
- Merkel Cell Carcinoma
- Merkel Cell Polyomavirus Infection
- Viral Encephalitis

## Interventions

- **BIOLOGICAL:** Allogeneic BK-specific Cytotoxic T-lymphocytes
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02479698
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-07-23
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479698, "Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02479698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*